Researchers in Australia have developed an innovative digital tool that can rapidly and accurately identify cancer patients who develop immune-related colitis, a potentially serious side effect of immunotherapy.
The tool was created by Peter MacCallum Cancer Centre and uses a clinician-verified “digital phenotype”, a computer algorithm that analyzes electronic medical records to detect immune-related colitis. The inflammatory bowel condition affects up to 50 percent of patients receiving immune checkpoint inhibitor immunotherapy.
According to the research team, the new technology replaces time-consuming manual case reviews with a fast and reliable method that can identify affected patients with a high degree of accuracy.
Lead researcher Jasmine Teng said the tool demonstrates how existing healthcare data can be used to improve patient outcomes and advance medical research.
“This tool represents a significant step forward in how we can harness the power of data that already exists within our health system,” Teng said.
Researchers believe the technology could help identify biomarkers that predict which patients are most likely to develop immune-related colitis. This would allow doctors to personalize immunotherapy treatments and improve the early management of side effects.
The ability to identify patients experiencing immune-related colitis on a large scale is expected to open new opportunities for research and provide valuable clinical insights that were previously difficult to obtain.
Experts say the development highlights the growing role of digital health technologies and data-driven tools in improving cancer care, treatment monitoring, and patient safety.
Stay Connected with ProPakistani
Get the latest international news and global stories wherever you prefer.
Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.
